Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF

被引：0
|
作者：
Joseph Gathe
Jose R. Arribas
Jan Van Lunzen
Will Garner
Rebecca M. Speck
Randall Bender
Sanatan Shreay
Thai Nguyen
机构：
[1] Therapeutic Concepts,
[2] PA,undefined
[3] Hospital La Paz,undefined
[4] IdiPaz,undefined
[5] Universitaetsklinikum Hamburg-Eppendorf,undefined
[6] Gilead Sciences,undefined
[7] Inc.,undefined
[8] Evidera,undefined
来源：
The Patient - Patient-Centered Outcomes Research | 2015年 / 8卷
关键词：
Physical Component Summary; Mental Component Summary; Tenofovir Disoproxil Fumarate; Mental Component Summary Score; Emtricitabine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：445 / 454
页数：9
相关论文
共 33 条
  • [11] Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
    Pozniak, Anton
    Arribas, Jose R.
    Gathe, Joseph
    Gupta, Samir K.
    Post, Frank A.
    Bloch, Mark
    Avihingsanon, Anchalee
    Crofoot, Gordon
    Benson, Paul
    Lichtenstein, Kenneth
    Ramgopal, Moti
    Chetchotisakd, Ploenchan
    Custodio, Joseph M.
    Abram, Michael E.
    Wei, Xuelian
    Cheng, Andrew
    McCallister, Scott
    SenGupta, Devi
    Fordyce, Marshall W.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 71 (05) : 530 - 537
  • [12] Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
    Post, Frank A.
    Tebas, Pablo
    Clarke, Amanda
    Cotte, Laurent
    Short, William R.
    Abram, Michael E.
    Jiang, Shuping
    Cheng, Andrew
    Das, Moupali
    Fordyce, Marshall W.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 74 (02) : 180 - 184
  • [13] Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study
    Orrell, Catherine
    Hagins, Debbie P.
    Belonosova, Elena
    Porteiro, Norma
    Walmsley, Sharon
    Falco, Vicenc
    Man, Choy Y.
    Aylott, Alicia
    Buchanan, Ann M.
    Wynne, Brian
    Vavro, Cindy
    Aboud, Michael
    Smith, Kimberly Y.
    LANCET HIV, 2017, 4 (12): : E536 - E546
  • [14] Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
    Orkin, Chloe
    DeJesus, Edwin
    Ramgopal, Moti
    Crofoot, Gordon
    Ruane, Peter
    LaMarca, Anthony
    Mills, Anthony
    Vandercam, Bernard
    de Wet, Joseph
    Rockstroh, Jurgen
    Lazzarin, Adriano
    Rijnders, Bart
    Podzamczer, Daniel
    Thalme, Anders
    Stoeckle, Marcel
    Porter, Danielle
    Liu, Hui C.
    Cheng, Andrew
    Quirk, Erin
    SenGupta, Devi
    Cao, Huyen
    LANCET HIV, 2017, 4 (05): : E195 - E204
  • [15] Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1:48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial
    Daar, Eric S.
    Dejesus, Edwin
    Ruane, Peter
    Crofoot, Gordon
    Oguchi, Godson
    Creticos, Catherine
    Rockstroh, Juergen K.
    Molina, Jean-Michel
    Koenig, Ellen
    Liu, Ya-Pei
    Custodio, Joseph
    Andreatta, Kristen
    Graham, Hiba
    Cheng, Andrew
    Martin, Hal
    Quirk, Erin
    LANCET HIV, 2018, 5 (07): : E347 - E356
  • [16] Tenofovir disoproxil fumarate and emtricitabine maintenance strategy in virologically controlled adults with low HIV-1 DNA: 48 week results from a randomized, open-label, non-inferiority trial
    Prazuck, Thierry
    Verdon, Renaud
    Le Moal, Gwenael
    Ajana, Faiza
    Bernard, Louis
    Sunder, Simon
    Roncato-Saberan, Mariam
    Ponscarme, Diane
    Etienne, Manuel
    Viard, Jean-Paul
    Pasdeloup, Thierry
    Darasteanu, Iuliana
    Pialoux, Gilles
    de la Blanchardiere, Arnaud
    Avettand-Fenoel, Veronique
    Parienti, Jean-Jacques
    Hocqueloux, Laurent
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (06) : 1564 - 1572
  • [17] Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older: week 48 results from a phase 3b, open-label trial
    Maggiolo, F.
    Rizzardini, G.
    Molina, J. M.
    Pulido, F.
    DeWit, S.
    Vandekerckhove, L.
    Berenguer, J.
    D'Antoni, M.
    Blair, C.
    Chuck, S.
    Piontkowsky, D.
    Martin, H.
    McNicholl, I.
    Payne, B.
    Gallant, J.
    HIV MEDICINE, 2020, 21 : 17 - 17
  • [18] Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine
    David Wohl
    Amanda Clarke
    Franco Maggiolo
    Will Garner
    Marianne Laouri
    Hal Martin
    Erin Quirk
    The Patient - Patient-Centered Outcomes Research, 2018, 11 : 561 - 573
  • [19] Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial
    Eron, Joseph J., Jr.
    Lelievre, Jean-Daniel
    Kalayjian, Robert
    Slim, Jihad
    Wurapa, Anson K.
    Stephens, Jeffrey L.
    McDonald, Cheryl
    Cua, Eric
    Wilkin, Aimee
    Schmied, Brigitte
    McKellar, Mehri
    Cox, Stephanie
    Majeed, Sophia R.
    Jiang, Shuping
    Cheng, Andrew
    Das, Moupali
    SenGupta, Devi
    LANCET HIV, 2019, 6 (01): : E15 - E24
  • [20] Patient-Reported Symptoms Over 48Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine
    Wohl, David
    Clarke, Amanda
    Maggiolo, Franco
    Garner, Will
    Laouri, Marianne
    Martin, Hal
    Quirk, Erin
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2018, 11 (05): : 561 - 573
1234